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BACKGROUND: This study examined the prevalence and correlates of skin cancer screening behaviours among individuals at high risk
of developing melanoma due to strong family history.
METHODS: A total of 120 individuals with a known family-specific CDKN2A mutation (72% response rate) completed a self-report
questionnaire assessing annual frequency of skin self-examination (SSE), clinical skin examination (CSE) and a variety of potential
demographic, clinical and psychosocial correlates.
RESULTS: In the past 12 months, 50% of participants reported engaging in SSE at least four times, and 43% of participants had
undergone at least one CSE. Engagement in SSE was associated with doctor recommendation (b¼1.77, P¼0.001), confidence in
one’s ability to perform SSE (b¼1.44, Po0.0001), positive beliefs about melanoma treatment (b¼0.77, P¼0.002) and intention to
perform SSE in the future (b¼1.69, Po0.0001). These variables accounted for 59% of the variance in SSE behaviour. Further,
information-seeking style moderated the relationship between anxiety and SSE (b¼1.02, P¼0.004). Annual uptake of CSE was
associated with doctor recommendation (b¼2.21, Po0.0001) and intention to undergo CSE in the future (b¼1.19, P¼0.001).
CONCLUSION: In comparison with clinical guidelines, it appears that individuals at high risk of developing melanoma engage in
suboptimal levels of skin surveillance. Improved doctor–patient communication, as well as psycho-education and behavioural
support, may be viable means of improving early skin cancer detection behaviours in this high-risk population.
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Despite more than 30 years of community education on skin
cancer prevention and early detection, Australia retains the
unwanted reputation as the melanoma epicentre of the world.
With over 10000 cases diagnosed annually, melanoma is the fourth
most common cancer in Australia, with one in 14 males and one in
23 females expected to develop melanoma in their lifetime (Tracey
et al, 2007). National melanoma mortality is relatively stable and
lower than that for other common cancers; however, melanoma
has a disproportionately heavy impact on productive years of life
lost because it is the most common cancer in young adults aged
between 15 and 45 years (Australian Institute of Health and
Welfare Australasian Association of Cancer Registries, 2004).
Although the 5-year survival rate for localised melanoma is 96%,
5-year survival rates for regional and distant-stage diseases are
63 and 34%, respectively. With B20% of melanomas diagnosed
with local or regional spread, the need to identify and address
barriers to early disease detection is clear, particularly in those at
increased risk.
An estimated 10% of melanoma cases will have at least one
(and most only one) first-degree relative (FDR) with a confirmed
melanoma diagnosis. Many of these familial clusters will be
because of chance or shared environmental influences; however,
at a minimum, 2% of all cases represent genuine high-risk
kindreds potentially resulting from the inheritance of uncommon,
major melanoma susceptibility genes (Easton et al, 1991; Aitken
et al, 1994). Germline mutations in two genes, CDKN2A and
(rarely) CDK4, have been shown to cause inherited melanoma
susceptibility with high penetrance (Bishop et al, 2002; Hayward,
2003; Kefford and Mann, 2003), and a third such locus has
recently been identified on chromosome 1p22 (Gillanders et al,
2003). There is wide variation in estimates of risk conferred by
carrying a pathogenic CDKN2A mutation, and strong evidence
suggests that risk varies across different populations (Bishop
et al, 2002), and is influenced by other independent risk factors
for melanoma such as level of exposure to ultraviolet radiation
(Cannon-Albright et al, 1994; Goldstein et al, 1998), skin
pigmentation and freckling (Palmer et al, 2000; van der Velden
et al, 2001), and potentially by modifier genes which may, in
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scertain families, also be associated with the presence of
atypical nevi (Tucker et al, 1993). In the context of familial
melanoma in Australia, estimates of risk conferred by CDKN2A
mutation are 10–20 times greater than that in the general
population.
Evidence-based guidelines for the clinical management of
individuals at high risk of developing melanoma recommend that
such persons be educated to recognise and document lesions
suggestive of melanoma, perform skin self-examination (SSE)
regularly (i.e., monthly) and engage in bi-annual full body
skin examination conducted by a clinician and supported by
dermoscopy and total body digital photography, as required
(Australian Cancer Network, 2008). While there have been no
controlled trials evaluating the impact of clinical skin examination
(CSE) on melanoma mortality, prospective studies of high-risk
groups have repeatedly demonstrated that the average thickness of
melanomas detected is reduced under regular surveillance
.
(e.g., Carli et al, 2003). Therefore, to the extent that the prognosis
of primary melanoma is related to its thickness, surveillance may
be inferred to benefit such patients. It is also well established that
a large proportion of melanoma patients (44–71%) detect their
own malignant lesion (Brady et al, 2000; Robinson et al, 2002;
McPherson et al, 2006). Case–control evidence indicates that
performance of SSE is associated with a reduced risk of advanced
disease (Berwick et al, 1996), and that heightened skin awareness
may increase the chances of survival (Berwick et al, 2005). Thus,
SSE and CSE are critical components of early detection
programmes in melanoma.
Yet, despite the importance of skin surveillance, very little is
known about the prevalence or predictors of these behaviours
among those at highest risk of melanoma. Widely accepted
theoretical models of health behaviour, such as the Transactional
Model of Stress and Coping, posit that the beliefs and appraisals
people form in relation to their health and illness experiences are
closely related to the decisions they make and the ways in which
they cope with health threats (Folkman and Guer, 2000; Glanz et al,
2002). According to the Transactional Model, variations in these
appraisals will evoke different individual responses to the same
health threat. When faced with a stressor (e.g., melanoma risk), a
person evaluates the potential threat and forms a judgment about
the personal significance of the event as stressful, controllable,
challenging or irrelevant (i.e., perceived risk and causal
attributions). Secondary appraisal follows, which is an assessment
of the person’s coping resources and options, as well as beliefs
about what one can do about the situation (i.e., self-efficacy and
response efficacy). Actual coping efforts aimed at regulation of the
problem give rise to outcomes of the coping process, including
emotional well-being and health behaviours. Dispositional coping
styles (e.g., information-seeking style) may also have a role, with
generalised ways of behaviour influencing a person’s emotional
or functional response to the stressor, and these styles generally
remain relatively stable across time and situations. When
considering adherence to melanoma-related health behaviours
such as SSE and CSE, according to the Transactional Model, an
individual is more likely to engage in these behaviours if he or she
perceives the threat of melanoma as high, if one believes one is
capable of performing the required actions and that these actions
will be effective in reducing melanoma risk, and if the required
knowledge and support is available. However, application of these
models to the setting of familial melanoma has not been
investigated.
Therefore, the aims of the present study were two-fold: (1) to
examine the annual frequency of SSE and CSE practices in a
sample of individuals at high risk of developing melanoma due to
strong family history and an identified family-specific mutation in
the CDKN2A gene; (2) to identify the demographic, clinical and
psychosocial factors associated with the uptake of these skin
cancer screening behaviours.
MATERIALS AND METHODS
Participants
Individuals with a strong family history of melanoma (i.e., families
comprising at least three relatives with a confirmed melanoma
diagnosis) and a known family-specific CDKN2A mutation were
ascertained via the Westmead Institute for Cancer Research/
University of Sydney centre of the Genetic Epidemiology of
Melanoma study. This is now part of the international GenoMEL
consortium (http://www.genomel.org), a multidisciplinary study of
the genetic epidemiology of melanoma (Holland et al, 1999; Bishop
et al, 2002; Goldstein et al, 2006). A detailed description of
ascertainment into the larger study has been published elsewhere
(Holland et al, 1999). Briefly, multiple-case melanoma families
have been ascertained from South Eastern Australia to the Sydney
arm of this study for over 18 years through either: (i) a family
member who attended the Sydney Melanoma Unit/Melanoma
Institute Australia (the largest dedicated melanoma treatment
service in the world), the Victorian Melanoma Service or other
clinics, for treatment of melanoma, (ii) referral from health
professionals such as clinical geneticists or dermatologists or
occasionally, (iii) self-referral after media publicity of melanoma.
Data on family structure, cancer history, illness characteristics,
skin phenotype, other melanoma risk factors and genotype are
collected as part of this study; however, participants are not
systematically provided with any educational materials about
melanoma risk.
Fully consented individuals were eligible for the present study
if a family-specific mutation in the CDKN2A gene had been
identified via the GenoMEL protocol. Ineligibility criteria included:
having previously undergone genetic testing for melanoma risk in
the clinical setting, inability to give informed consent and current
diagnosis with metastatic cancer.
Procedure
This paper presents the baseline data from a prospective cohort
study of candidates for genetic testing for melanoma risk
(Kasparian et al, 2009b). Identification of potentially pathogenic
mutations in 18 families made genetic testing possible and, in
accordance with the larger study protocol, all participating
members of these families (N¼176) were informed by letter
about the availability of genetic counselling and testing in January
2005 and were simultaneously offered to participate in the current
study. Individuals who did not decline study participation were
telephoned 14 days after invitation letters were mailed to
determine their interest in participating. Interested individuals
were mailed the first (‘baseline’) questionnaire and a pre-paid
envelope. Reminder letters and phone calls were made as
appropriate to participants who did not complete the question-
naire within a specified time. The appropriate Institutional Review
Board gave approval and informed consent was obtained from all
participants.
Measures
Clinical characteristics were accessed through the Sydney-based
Genetic Epidemiology of Melanoma database and a pedigree was
created for each participating family, containing data on: total
number of individuals affected by melanoma, total number of
FDRs and second-degree relatives (SDRs) deceased due to
melanoma, and personal history of melanoma. In the absence of
a published algorithm for calculation of lifetime risk of melanoma,
estimated risk of being a CDKN2A mutation carrier was assigned
for each participant before genetic testing. Given the presence of a
family-specific CDKN2A mutation, participants with a personal
history of melanoma were assigned a 100% risk of carrying
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sa mutation. Amongst unaffected participants, those whose closest
affected relative was a FDR or SDR were assigned a 50 or 25% risk,
respectively, and those with no known FDR or SDR with melanoma
were assigned a risk of 12.5%.
The study questionnaire elicited the following data:
(1) Demographic characteristics: age, sex, marital status, educa-
tional level, country of birth and occupational environment.
(2) Perceived risk of developing melanoma was assessed using
five items described in an earlier publication (Kasparian et al,
2009b). On the basis of factor analytic results, a summary
score was calculated for these items for analysis (Cronbach’s
alpha¼0.73).
(3) Causal attributions for melanoma were assessed via 11 items
based on our previous qualitative work (Kasparian et al, 2007,
2008). Three causal factors were assessed: sun exposure (five
items), genetics (three items) and uncontrollable factors (e.g.,
chance, three items). Participants rated the importance of
each item as a cause of melanoma on a 5-point Likert rating
scale from 1 (‘not at all important’) to 5 (‘extremely
important’). A summary score was calculated for each of the
three factors for analysis.
(4) Self-efficacy for SSE was assessed using a single item to
identify participants’ confidence in their ability to accurately
and regularly conduct SSE. Response options ranged from
1 (‘not at all confident’) to 5 (‘extremely confident’), with
higher scores indicating greater self-efficacy.
(5) Response efficacy was assessed using two items to identify
participants’ beliefs about the efficacy of: (i) CSE as a means
of early melanoma detection and (ii) medical treatment as a
means of curing melanoma. Participants responded to each
item using a 5-point Likert scale from 1 (‘strongly disagree’)
to 5 (‘strongly agree’). Higher scores indicated more negative
beliefs about response efficacy.
(6) Patient communication with their doctor about family history
of melanoma was assessed using one item. Participants were
asked whether they had ever discussed their family history of
melanoma with their doctor. Response options were ‘yes’, ‘no’
and ‘unsure’.
(7) Doctor recommendation was assessed using three items. For
SSE, participants were asked to indicate whether a doctor or
other health professional had ever: (i) recommended the person
to regularly examine his or her skin for signs of changes in spots
or moles and (ii) provided instruction or education about the
best way to perform this procedure. For CSE, one item assessed
whether a doctor had ever suggested the participant see a health
professional for skin cancer screening.
(8) Behavioural intentions were assessed using two items to
identify the likelihood that the participant would engage in
SSE or CSE in the next 12 months. Participants indicated their
screening intentions on a 5-point Likert scale ranging from
1 (‘not at all likely’) to 5 (‘extremely likely’).
(9) Melanoma-specific distress was assessed with the 15-item
Impact of Events Scale (IES; Horowitz et al, 1979).
Participants rated the frequency of intrusive and avoidant
cognitions and behaviours regarding their melanoma risk
using a 4-point frequency scale. A total score X40 is consi-
dered indicative of a significant stress response (Horowitz
et al, 1979; Cella et al, 1990). Internal consistency for the IES
total score was 0.89.
(10) General anxiety and depression: The Hospital Anxiety and
Depression Scale has two 7-item subscales measuring anxiety
and depression (Zigmond and Snaith, 1983). Each item has
four response options ranging from 0 (‘not at all’) to 3 (‘very
much’), yielding scores from 0 to 21 for each subscale.
Subscale scores X8 indicate potentially elevated distress
(Zigmond and Snaith, 1983). Internal consistency was 0.85
and 0.74 for the anxiety and depression subscales, respectively.
(11) Information-seeking style was assessed using the Miller
Behavioural Style Scale (Miller, 1987; Muris and Schouten,
1994). Respondents were asked to imagine four hypothetical
stress-invoking scenarios of a largely uncontrollable nature.
Each scenario was followed by eight responses indicative of
either high or low information-seeking (or monitoring) style.
For the analysis, individuals were categorised as either low or
high monitors on the basis of how they anticipated their
response(s) to these threat-related cues, using a median split
(Miller, 1996).
(12) Screening behaviours: SSE and CSE behaviours were the
outcome variables for this study. Skin self-examination was
defined as ‘the careful and deliberate checking for changes in
spots or moles on all areas of your skin, including those areas
rarely exposed to the sun’ (Manne et al, 2004). Participants
indicated the number of times they had engaged in SSE over
the past 12 months using a 5-point Likert scale ranging from
1 (‘not at all’) to 5 (‘weekly’). Participants also indicated
their use of a mirror or the help of another person when
performing SSE on a 5-point scale from 1 (‘never’) to 5
(‘always’). Participants were then asked to indicate whether
they had ever had a CSE and if so, the number of times they
had undertaken CSE in the past 12 months, giving the
approximate date of each examination (Manne et al, 2004).
Data analysis
Data were analysed using SPSS 17.0 and SAS 9.1. Differences
between participants and non-participants for non-psychological
variables were assessed using Pearson’s w
2-tests, linear-by-linear
association tests or t-tests, as appropriate. For the bivariate
analyses, the behavioural outcome variables were treated as
ordinal variables. Accordingly, Mann–Whitney U-tests or Kruskal–
Wallis tests were used to examine associations between categorical
predictor variables and behavioural outcomes, and Spearman’s
rank correlation coefficients (rs) were used to examine asso-
ciations between continuous predictor variables and behavioural
outcomes.
To assess determinants of screening behaviours, two separate
linear regressions were performed. Predictor variables with
Pp0.10 in the bivariate analyses were included in initial multi-
variate models (Hosmer and Lemeshow, 2000). A progressive,
backward elimination modelling strategy was employed until a
final model was obtained containing only variables with Po0.05.
Owing to their importance, age, sex, educational level and marital
status were included in all regression models as potential
confounders. When the preliminary final model for each regres-
sion analysis had been built, each potential confounder was
removed, one at a time. If its removal resulted in a 410% change
in the coefficient of any predictor, the variable was considered a
confounder and was retained in the final model (Kleinbaum et al,
1987). Multi-collinearity of predictor variables was checked but no
problem was detected. Two-way interactions among terms in the
final models were tested by adding them one at a time. In all
regression models, analyses included data from members of the
same family. To account for potential dependence among these
data, correlations among responses of individuals in the same
family cluster were allowed for using generalised estimating
equations for linear regression (Liang and Zeger, 1986). For scale
variables, the reported value of b represents the change in the
outcome variable per unit increase in the scale.
RESULTS
Response rates and sample characteristics
Of the 176 individuals who were considered eligible for study
participation, contact details were not available for 10, therefore,
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s166 individuals were approached for participation. Of these, 120
individuals returned questionnaire data, yielding a response rate of
72% among eligible, successfully contacted participants. The mean
age of the sample was 50 years (s.d.¼15.5), with males (48%) and
females (52%) represented equally. The majority of the sample
(74%) was married, 11% had completed a university degree and
96% had been born in Australia. In terms of occupational
environment, 52% of participants worked primarily indoors, 22%
worked outdoors and 23% spent equal amounts of time indoors
and outdoors. One-third of the sample (31%) had a personal
history of melanoma, 62% had at least three FDRs or SDRs with a
previous melanoma and 41% had lost a family member due to
melanoma. Participants and non-participants did not differ
significantly by age, sex, personal history of melanoma or number
of affected relatives. Psychological characteristics of the sample are
shown in Table 1. The majority of the sample (92% of affected and
69% of unaffected participants) reported having discussed their
family history of melanoma with their doctor. Participants without
a personal history of melanoma were less likely to have discussed
their family history with their doctor than those with a previous
melanoma diagnosis (w
2¼7.04, df¼1, P¼0.008). In all, 50%
of participants reported receiving a recommendation from a
health professional to have a CSE and 59% had received
a recommendation to perform SSE, although only 34% reported
that the clinician had provided education or instruction on how to
perform SSE. A greater proportion of affected (86%) than
unaffected (48%) participants reported receiving a recommenda-
tion for SSE (w
2¼15.45, df¼1, Po0.001). Similarly, more affected
(77%) than unaffected (39%) participants reported receiving a
recommendation for CSE (w
2¼14.16, df¼1, Po0.001).
Engagement in skin cancer screening behaviours
Figures 1 and 2 illustrate annual frequency of SSE and CSE,
respectively; data are presented separately for those previously
affected or unaffected by melanoma. Overall, 21% of participants
reported performing SSE once per month and 17% reported
weekly performance of SSE. In contrast, 15% of participants had
not performed SSE at all in the past 12 months and 36% ‘never’
or ‘rarely’ used a mirror or enlisted the help of another person
when performing SSE. Those previously affected by melanoma
reported significantly greater engagement in SSE over the past
year (mean scale score M¼3.39, s.d.¼1.34) than unaffected
(M¼2.67, s.d.¼1.31) participants (Z¼2.71, P¼0.007). Of those
who reported not receiving a recommendation for SSE (n¼49),
29% had not undertaken any form of SSE in the past 12 months. In
terms of CSE behaviours, 43% of participants had engaged in CSE
at least once in the past 12 months, with only 17% adhering to the
recommended biannual uptake of CSE. The majority of the sample
(57%) had no CSE in the past 12 months and 27% of participants
never had a CSE. Affected participants (M¼1.03 times, s.d.¼0.85)
reported significantly higher CSE uptake in the past 12 months
than unaffected (M¼0.48, s.d.¼0.89) participants (Z¼3.86,
P¼0.0005). Of those who reported not receiving a recommenda-
tion for CSE (n¼59), 88% had no CSE in the past 12 months.
Correlates of SSE behaviour
Demographic, clinical and psychological variables associated
with SSE behaviour at the bivariate level are presented in Table 2.
After allowing for the other predictors, doctor recommendation
(b¼1.77, 95% confidence interval (CI): 1.26–2.48, P¼0.001),
Table 1 Mean scores for psychological variables, presented separately
for those previously affected or unaffected by melanoma, as well as for the
total sample
Affected
(n¼36)
Unaffected
(n¼84)
Total sample
(n¼120)
Variable Mean (s.d.) Mean (s.d.) Mean (s.d.)
Perceived risk 3.81 (0.66) 3.35 (0.74) 3.48 (0.74)
Causal attributions
Perceived importance of
sun exposure
4.32 (0.62) 4.14 (0.61) 4.19 (0.62)
Perceived importance of
genetics
4.52 (0.52) 4.26 (0.69) 4.34 (0.65)
Perceived importance of
uncontrollable factors
1.70 (0.99) 1.53 (0.67) 1.58 (0.77)
Self-efficacy for SSE 3.47 (1.06) 2.65 (0.91) 2.90 (1.02)
Perceived efficacy of CSE 1.33 (0.63) 1.44 (0.67) 1.41 (0.66)
Perceived efficacy of melanoma
treatment
1.61 (0.84) 2.00 (0.99) 1.88 (0.96)
Intention to engage in SSE
in future
3.78 (1.10) 3.50 (1.09) 3.58 (1.10)
Intention to engage in CSE
in future
3.97 (1.16) 2.98 (1.41) 3.28 (1.41)
Melanoma-specific distress 10.78 (10.86) 5.49 (10.04) 7.08 (10.53)
General anxiety 4.89 (3.29) 5.68 (3.91) 5.44 (3.74)
General depression 2.94 (2.76) 3.55 (2.63) 3.37 (2.67)
Information-seeking style 8.14 (3.56) 8.45 (3.28) 8.36 (3.35)
Abbreviations: CSE¼clinical skin examination; SSE¼skin self-examination.
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Figure 1 Reported frequency of SSE in the past 12 months, presented
separately for those previously affected or unaffected by melanoma.
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Figure 2 Reported frequency of CSEs in the past 12 months, presented
separately for those previously affected or unaffected by melanoma.
Skin surveillance in individuals at high risk of melanoma
NA Kasparian et al
1505
British Journal of Cancer (2010) 103(10), 1502–1509 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sconfidence in one’s ability to perform SSE (b¼1.44, 95% CI:
1.20–1.72, Po0.0001), positive beliefs about melanoma treatment
(b¼0.77, 95% CI: 0.65–0.91, P¼0.002) and intention to perform
SSE in the future (b¼1.69, 95% CI: 1.45–1.99, Po0.0001) were
independently associated with SSE uptake. Further, as illustrated
by Figure 3, information-seeking style moderated the relationship
between anxiety and SSE behaviour (b¼1.02, 95% CI: 1.01–1.03,
P¼0.004). For ‘high monitors’, reported SSE was greater for those
with higher generalised anxiety levels, compared with those with
lower anxiety. In contrast, no difference in SSE behaviour was
found for ‘low monitors’ across levels of anxiety. Overall, this
model accounted for 59% of the variance in SSE behaviour.
Correlates of CSE behaviour
Variables associated with CSE behaviour at the bivariate level are
presented in Table 3. After allowing for education and the other
predictor, doctor recommendation (b¼2.21, 95% CI: 1.65–2.94,
Po0.0001) and intention to undergo CSE in the future (b¼1.19,
95% CI: 1.07–1.32, P¼0.0008) were independently associated with
CSE uptake. Overall, this model accounted for 40% of the variance
in CSE uptake.
DISCUSSION
This study is among the first to investigate the frequency of self-
reported skin cancer screening behaviours, as well as the correlates
of these behaviours, in a sample of individuals at high risk of
developing melanoma due to strong family history. Overall, in
comparison with evidence-based clinical practice guidelines
(Australian Cancer Network, 2008), we found that a substantial
subset of individuals at increased risk of developing melanoma
engage in suboptimal levels of skin cancer screening and
surveillance. Over one-quarter of participants in this high-risk
sample had never had a CSE, and only 17% reported adherence to
the recommended biannual uptake of CSE. A similar pattern of
results was found for SSE, with only 21% of the sample reporting
monthly performance of SSE. Those without a personal history of
melanoma reported significantly lower levels of screening, as well
as lower levels of doctor–patient communication about melanoma
and health-related behaviours. Given the genetic risk status of the
families in this study, as well as the environmental risk associated
with living in Australia, these findings are cause for concern.
Drawing comparisons between these findings and the screening
behaviours of other high-risk melanoma samples is difficult,
because of the paucity of published data. The low rate of monthly
SSE observed in our sample is similar to that reported for
individuals from CDKN2A mutation-positive families in the United
States (17%; Aspinwall et al, 2008), as well as melanoma survivors
(15%; Manne and Lessin, 2006) and individuals with multiple
Table 2 Bivariate analysis of demographic, clinical and psychological
variables associated with performance of skin self-examination in the past
12 months
Test statistics
Variable
Mean SSE
(s.d.) Zd f P
Demographic variables
Sex
Male 2.95 (1.41) 0.49 0.62
Female 2.82 (1.31)
Marital status
Currently married 2.85 (1.26) 0.22 0.82
Not married 2.97 (1.62)
Education level
University degree 3.00 (1.29) 0.40 0.69
No university degree 2.87 (1.37)
Age
a 1.86 1 0.17
Occupational environment
b
Indoors 2.63 (1.27) 3.65 2 0.16
Outdoors 2.93 (1.27)
Even time indoors and outdoors 3.22 (1.50)
Clinical variables
Personal history of melanoma
Previous melanoma 3.39 (1.33) 2.71 0.007
No previous melanoma 2.67 (1.31)
Number of FDRs and SDRs
affected by melanoma
a
5.66 1 0.02
Number of FDRs and SDRs deceased
owing to melanoma
a
0.026 1 0.87
Objective CDKN2A mutation carrier risk
b
100% 3.39 (1.34) 7.86 2 0.02
50% 2.75 (1.36)
25% or less 2.53 (1.24)
Doctor recommendation for SSE
Yes 3.31 (1.31) 4.20 o0.0001
No 2.27 (1.19)
Doctor instruction on SSE
Yes 3.49 (1.23) 3.62 o0.0001
No 2.57 (1.32)
Psychological variables rs P
Perceived risk 0.15 0.10
Causal attributions
Sun exposure 0.13 0.17
Genetics 0.05 0.59
Uncontrollable factors 0.02 0.82
Self-efficacy for SSE 0.52 o0.0001
Perceived efficacy of melanoma treatment  0.25 0.007
Intention to engage in SSE in future 0.61 o0.0001
Melanoma-specific distress 0.25 0.006
General anxiety 0.09 0.34
General depression 0.06 0.53
Information-seeking style
c ZP
High monitor 2.80 (1.38) 0.66 0.51
Low monitor 2.94 (1.31)
Abbreviations: FDR¼first-degree relatives; SDR¼second-degree relatives;
SSE¼skin self-examination. To interpret mean SSE scores, response options were:
1¼‘not once’, 2¼‘one to three times per year’, 3¼‘four to eight times per year’,
4¼‘once per month’ and 5¼‘once per week’.
aLinear-by-linear association test.
bKruskall–Wallis.
cMann–Whitney U. Bold type is used to indicate statistical
significance at the Po0.05 level.
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Figure 3 Mean annual frequency of SSE as a function of the interaction
between information seeking style (low vs high monitoring) and anxiety,
measured by the Hospital Anxiety and Depression Scale.
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sdysplastic nevi (10–20%; Oliveria et al, 2004). Although it is
possible that low levels of SSE may be associated with a greater
reliance on regular CSE for early detection of skin cancer – with
patients believing they are better off ‘leaving it up to the experts’ –
this is highly unlikely in the present sample. Only 43% of
participants had engaged in CSE in the past 12 months, a rate
lower than the 52% observed by Aspinwall et al (2008) in their
recent study of CDKN2A mutation-positive families. A post hoc
analysis was conducted to investigate this possibility, and CSE and
SSE uptake were found to be positively correlated (rs¼0.22,
P¼0.02), indicating that an individual who conducted CSE was
more – rather than less – likely to also conduct SSE. It is also
notable that a sizeable proportion of the present sample reported
weekly engagement in thorough SSE (i.e., over-screening; see
Figure 1), a finding which is not uncommon among those at
increased risk (Manne and Lessin, 2006; Aspinwall et al, 2008), but
which is suggestive of a lack of understanding of the rationale
for SSE. Weekly performance of SSE, reported by approximately
one-third of those with a personal history of melanoma, may serve
to diminish one’s capacity to detect subtle but important skin
changes. At the opposite end of the spectrum, 20% of participants
without a personal history of melanoma reported no engagement
in SSE over the past 12 months. Thus, across a range of high-risk
melanoma populations from a variety of different geographical
locations, there is growing evidence of inadequate uptake of skin
cancer screening behaviours.
From a theoretical perspective, the study findings provide
partial support for the Transactional Model of Stress and Coping.
We found that the strongest predictor of both CSE and SSE
behaviour was having received a recommendation from a health
professional to perform screening. This finding is consistent with
the broader cancer literature which shows that doctor recommen-
dation is the single most important predictor of whether an
individual has ever had a cancer screening test or has recently
practiced screening (Rimer et al, 1991). This highlights the critical
role that clinicians have in encouraging and supporting patients’
uptake of skin cancer-related health behaviours. It also suggests
that clinician consultation may be a powerful yet relatively
inexpensive vehicle for health behaviour change in this setting,
with general practitioner or family physician consultations
providing opportune moments for health behaviour promotion.
For families with an inherited pattern of melanoma, genetic
consultations may also provide a unique opportunity for tailored
education and support with regard to skin cancer screening.
Coupled with the finding that behavioural intentions also have
a key role in determining uptake of CSE and SSE, this suggests
that doctor–patient communication may help to increase screen-
ing intentions as well as behaviours in high-risk melanoma
populations. The development of simple, evidence-based psycho-
educational tools, such as a tailored discussion guide or a health
behaviour ‘contract’, may serve to facilitate this communication
process and elicit strong behavioural intentions among patients. In
future work, researchers, clinicians and consumer representatives
could partner to develop and evaluate the efficacy and
cost-effectiveness of such tools in increasing skin cancer screening
adherence. Given that only 50% of our sample reported receiving
health professional advice about CSE, and only one-third reported
receiving instructions on how to perform SSE, there appears to be
considerable potential for improvement in this area.
In line with the Transactional Model, confidence in one’s ability
to perform SSE (i.e., self-efficacy) was also found to have an
independent role in determining engagement in SSE. This
reiterates the importance of not only educating patients about
the need to perform SSE, but also providing individuals with the
time and space to learn and practice the specific skills required
for adequate SSE. In a previous study involving individuals
with multiple dysplastic nevi, Oliveria et al, (2004) found that
participation in a brief educational intervention featuring the use
of digital photographs and nurse-delivered instruction on how to
use the photographs led to substantial improvements in reported
rates of SSE over a 4-month period. Education only, without the
practical skills-based component, failed to produce an increase in
SSE behaviour. Future studies could evaluate the efficacy of such
interventions over a longer period, and in different populations
(e.g., those with a strong family history of melanoma), to assess the
longevity of improvements in SSE. As has been found with other
health behaviour interventions (e.g., Myers et al, 2004), it may be
necessary to supplement the initial training session with periodic
Table 3 Bivariate analysis of demographic, clinical and psychological
variables associated with frequency of clinical skin examination in the past
12 months
Test statistics
Variable
Mean CSE
(s.d.) Zd f P
Demographic variables
Sex
Male 0.74 (1.00) 0.92 0.36
Female 0.56 (1.81)
Marital status
Currently married 0.68 (0.96) 0.26 0.80
Not married 0.56 (0.76)
Education level
University degree 1.00 (1.16) 1.20 0.23
No university degree 0.61 (0.87)
Age
a 0.54 1 0.46
Occupational environment
b
Indoors 0.69 (0.92) 4.24 2 0.12
Outdoors 0.36 (0.68)
Even time indoors and outdoors 0.74 (0.86)
Clinical variables
Personal history of melanoma
Previous diagnosis 1.03 (0.85) 3.86 o0.0001
No previous diagnosis 0.48 (0.89)
Number of FDRs and SDRs
affected by melanoma
a
2.92 1 0.09
Number of FDRs and SDRs
deceased owing to melanoma
a
0.40 1 0.53
Objective CDKN2A mutation carrier risk
b
100% 1.03 (0.85) 16.07 2 o0.0001
50% 0.53 (0.86)
25% or less 0.41 (0.95)
Doctor recommendation for CSE
Yes 1.14 (0.99) 6.69 o0.0001
No 0.14 (0.39)
Psychological variables rs P
Perceived risk 0.16 0.08
Causal attributions
Sun exposure 0.11 0.22
Genetics 0.12 0.22
Uncontrollable factors 0.04 0.65
Perceived efficacy of CSE  0.21 0.02
Perceived efficacy of melanoma treatment  0.13 0.17
Behavioral intention to perform CSE 0.54 o0.0001
Melanoma-specific distress 0.16 0.08
General anxiety  0.06 0.53
General depression  0.09 0.33
Information-seeking style
c ZP
High monitor 0.62 (0.84) 0.24 0.81
Low monitor 0.70 (0.99)
Abbreviations: CSE¼clinical skin examination; FDR¼first-degree relatives;
SDR¼second-degree relatives.
aLinear-by-linear association test.
bKruskall–Wallis.
cMann–Whitney U. Bold type is used to indicate statistical significance at the Po0.05
level.
Skin surveillance in individuals at high risk of melanoma
NA Kasparian et al
1507
British Journal of Cancer (2010) 103(10), 1502–1509 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sprompts to action, as well as opportunities for ‘checking in’ to
assess the adequacy and thoroughness of an individual’s SSE
technique. It is also imperative that future researchers monitor
emotional responses to SSE-related education, as anxiety levels
may increase as the focus on melanoma detection increases (for a
review see Kasparian et al, 2009a).
We also found that information-seeking style moderated the
relationship between anxiety and SSE behaviour. In particular,
high monitors with higher levels of anxiety reported greater
engagement in SSE than did high monitors with low anxiety.
In contrast, there was no difference in SSE for low monitors
across levels of anxiety. This finding is consistent with previous
theoretical and empirical work, and supports the notion that,
although anxiety drives high monitors to action, no amount of
anxiety will galvanise those with a tendency to avoid risk-related
information. It is possible, however, that higher anxiety in high
monitors may lead to overscreening or an unhealthy focus on one’s
skin and moles. Thus, it may be important for clinicians to explore
individuals’ beliefs about melanoma and SSE and to gently
challenge any misconceptions that may arise.
Contrary to our initial hypothesis, perceived risk was not
associated with screening uptake. In populations at an increased
risk of melanoma, the role of perceived risk in determining
screening behaviour is equivocal. Some studies have reported a
positive association between perceived risk and SSE (Robinson
et al, 2002), others have found only weak support for the
association between SSE and perceived risk (Manne et al, 2004),
and in other studies, perceived risk did not emerge as a predictor
of SSE uptake (Geller et al, 2003). These mixed findings suggest
that there may be some aspects of existing health behaviour
models that do not adequately account for the results found in
high-risk cancer populations, signalling the need to rethink
conceptualisations of health behaviour in these populations.
Recommendations for clinical practice and future research
It is hoped that these findings will contribute to the growing body
of evidence indicating an urgent need to bolster health promotion
and education efforts targeting populations at increased risk of
melanoma. The results of this study provide some guide as to the
key areas or ‘hot spots’ on which to focus attention when designing
supportive care interventions for melanoma survivors and those
at high risk of skin cancer. Clearly, it is imperative to engage
clinicians (e.g., dermatologists, general practitioners, nurses,
geneticists, genetic counsellors and psychologists) in the health
behaviour change process, given that clinician recommendation
was the strongest predictor of both CSE and SSE uptake. The
development of programs and resources to improve skin cancer
screening behaviours must include input and foster ownership
from those in clinical practice. The same can be said for consumer
representation. Without input from these key stakeholders,
prevention efforts in this setting are unlikely to succeed. It is also
critical that interventions address the role of psychological factors
in health behaviour change. To this end, it is recommended that
supportive care programs feature several components. First is
psycho-education, which includes information on melanoma and
melanoma risk management, education about the emotional,
behavioural, physical and practical issues faced by individuals at
increased risk of melanoma, exercises to assist in identifying and
understanding negative core beliefs about skin cancer and
screening, as well as tools to facilitate healthy coping strategies
and open communication between patients and clinicians. Second,
skills-based training is required to assist individuals in developing
both confidence and capability in self-screening techniques.
Third, sufficient time and space is needed for individuals to
explore and express their feelings and concerns about melanoma
with a caring professional who can listen attentively and try
to understand.
Given the limited available data on the screening practices of
those at high risk of melanoma, the findings of the present study
make an important contribution to the literature. However, this
study is not without its limitations. Owing to the cross-sectional
study design, the data cannot elucidate the causal direction of
associations. Because the findings are based on self-report, it is not
possible to rule out the influence of socially desirable responding;
however, given the low levels of adherence to clinical recommen-
dations, the influence of this is likely to have been minimal.
Further, the thoroughness of SSE was not directly assessed,
suggesting some bias in the way this may have been interpreted by
participants. Also, notification of the presence of a family-specific
mutation in the CDKN2A gene is an event that would be expected
to increase the self-perception of melanoma risk. In the present
study, all participants were notified of the presence of a family-
specific mutation in a single wave and no participants had
undergone individual genetic testing in the clinical setting. Thus, it
was not possible to examine the potential effect of time since
notification on skin cancer screening behaviours. This is an
important area for future research. Despite these limitations,
identifying the characteristics of those most likely to adhere to
screening recommendations (as well as the factors that may
contribute to non-adherence) may enhance the effectiveness of
supportive care programs and resources, as well as more
widespread public health messages about the importance of skin
cancer surveillance practices.
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